Predicting outcomes and side effects of radiation therapy for lung cancer using molecular markers
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer
This study is looking to make radiation therapy better for people with non-small cell lung cancer by using special tests to understand how their cancer is responding during treatment, so they can get the most effective care with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10829420 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for patients with non-small cell lung cancer (NSCLC) by using molecular biomarkers to personalize radiation therapy (RT). The study aims to identify changes in circulating tumor DNA (ctDNA) during treatment to predict patient outcomes and potential side effects. By developing personalized risk models, the researchers hope to enhance the effectiveness of RT and minimize toxicity for patients. This approach represents a shift towards precision medicine in oncology, specifically tailored for lung cancer patients undergoing radiation therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing radiation therapy.
Not a fit: Patients with other types of lung cancer or those not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer radiation therapy for lung cancer patients, improving their treatment outcomes and quality of life.
How similar studies have performed: Previous research has shown promise in using molecular markers for predicting treatment outcomes in various cancers, suggesting that this approach could be effective for lung cancer as well.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Diehn, Maximilian — Stanford University
- Study coordinator: Diehn, Maximilian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.